Gentherm Reports Sharp 2025 Net Income & EPS Decline Amid Record Revenue; Details Modine Acquisition & Recall Risks

summarizeSummary

Gentherm Inc. filed its annual 10-K report, revealing a significant drop in 2025 GAAP net income and EPS despite record revenue, alongside comprehensive details on its Modine acquisition and material product recall liabilities.

check_boxKey Events

• Significant Decline in 2025 Profitability

  Despite achieving record product revenue of $1.498 billion (up 2.9% from 2024), GAAP net income plummeted to $18.3 million in 2025 from $64.9 million in 2024, and diluted EPS fell sharply to $0.59 from $2.06.

• Detailed Modine Acquisition Terms

  The filing provides full details of the Reverse Morris Trust transaction to acquire Modine's Performance Technologies business, initially announced on January 29, 2026. Gentherm shareholders are expected to own approximately 60% of the combined entity, with a $210 million cash payment from SpinCo to Modine and a $790 million bridge loan facility committed for funding.

• Material Product Recall Liabilities Disclosed

  The company disclosed two significant automotive product recalls (VW in Feb 2024 for 261,257 vehicles and VW/Porsche in April 2025 for 13,508 vehicles) with potential material costs. Gentherm has not accepted financial responsibility for these and is pursuing discussions and indemnification claims.

• Ongoing Restructuring Initiatives

  Three restructuring plans were initiated in 2025 (EMEA, Asia, and a global Manufacturing Footprint Plan) to optimize operations, involving facility closures, relocations, and expected cash costs of $9-13 million and capital expenditures of $4-7 million.

auto_awesomeAnalysis

Gentherm's annual 10-K filing provides the full audited financial results for 2025, confirming a substantial decline in profitability despite achieving record revenue. This detailed report expands significantly on previously announced summary figures, offering critical insights into the company's financial health and future outlook. The comprehensive disclosure of the Modine acquisition terms, ongoing restructuring efforts, and significant product recall liabilities adds layers of complexity and risk for investors. The identified goodwill impairment risk in the Medical segment further highlights potential future challenges. Investors should carefully evaluate the impact of declining profitability and contingent liabilities against the strategic benefits of the Modine acquisition and operational restructuring.